- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07694089
Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas
A Randomized Trial of Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas
The purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery. The study will compare three approaches by placing participants in one of three study groups: standard dexamethasone (a steroid), no routine steroid treatment, and azeliragon, a study drug that may reduce brain swelling through a different pathway. Researchers want to determine whether these alternatives can control swelling while reducing some of the side effects associated with steroid use.
Participants in this study will be randomly assigned to one of three study groups. Participants will undergo their planned brain tumor surgery and receive the treatment assigned to their group. Study procedures are the same as their routine care and include physical and neurological examinations, blood tests, MRI scans, review of medical records, and collection of tumor tissue removed during surgery (optional). Most study visits will occur during routine medical care. Participants will be followed for approximately 24 months after surgery.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This study is a randomized Phase II trial because it is designed to evaluate the preliminary efficacy, safety, and feasibility of steroid avoidance and azeliragon as alternatives to dexamethasone for perioperative cerebral edema management in high-grade glioma. The trial uses an intermediate imaging-based efficacy endpoint, enrolls a modest sample size, and is intended to identify promising strategies for subsequent confirmation in a definitive Phase III study.
The trial compares three perioperative strategies-standard dexamethasone, complete steroid avoidance, and RAGE inhibition with azeliragon-to determine their relative safety and effectiveness in controlling cerebral edema following tumor resection. In addition to edema control, the study evaluates clinical, functional, and immunologic outcomes associated with perioperative corticosteroid exposure.
Despite widespread use, dexamethasone lacks prospective evidence defining its optimal perioperative role in glioma patients. This study addresses that gap by rigorously evaluating steroid avoidance and a mechanistically targeted alternative, with the goal of improving patient outcomes while minimizing treatment-related toxicity.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
Contatti e Sedi
Contatto studio
- Nome: Akshitkumar M Mistry, MD
- Numero di telefono: 502-276-5030
- Email: a.mistry@uoflhealth.org
Backup dei contatti dello studio
- Nome: UofL Health Brown Cancer Center
- Numero di telefono: 502-562-4370
Luoghi di studio
-
-
Kentucky
-
Louisville, Kentucky, Stati Uniti, 40202
- UofL Health Brown Cancer Center; University of Louisville Hospital
-
Contatto:
- UofL Health Brown Cancer Center
- Numero di telefono: 502-562-4370
-
Louisville, Kentucky, Stati Uniti, 40202
- UofL Health Jewish Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Descrizione
Inclusion Criteria:
Age ≥18 years at the time of screening
- Newly diagnosed supratentorial tumor with imaging characteristics consistent with high-grade glioma
- Candidate for craniotomy with planned resection of more than 50% of the contrast-enhancing tumor
- Midline shift ≤10 mm on preoperative imaging
- Limited pre-enrollment corticosteroid exposure (≤10 mg dexamethasone total and no chronic steroid use within 30 days)
- Karnofsky Performance Status ≥60
- Adequate organ function to undergo surgery and postoperative care as determined by the investigator
- Ability to provide informed consent and comply with study procedures
- Agreement to use effective contraception, when applicable
Exclusion Criteria:
Participants meeting any of the following will be excluded:
- Imaging or clinical features highly suggestive of primary CNS lymphoma or metastatic disease
- Posterior fossa tumors or lesions associated with high risk of brainstem compression
- Leptomeningeal or widely disseminated disease
- Clinical conditions requiring immediate corticosteroid therapy
- Prior exposure to high-dose corticosteroids (>10 mg dexamethasone) or chronic steroid use within 30 days
- Active systemic illness that increases surgical risk, including uncontrolled infection, coagulopathy, or severe cardiopulmonary disease
- Pregnancy or breastfeeding
- Known immunodeficiency or chronic infection requiring immunosuppressive therapy
- Use of investigational agents within 30 days or concurrent use of immunosuppressive medications not permitted by protocol
- Known hypersensitivity to azeliragon
- Inability to undergo MRI due to contraindications such as incompatible implants or severe claustrophobia
- Life expectancy less than 3 months as determined by the investigator
- Participation in another interventional clinical trial prior to initiation of standard adjuvant therapy Vulnerable Populations: This study will not enroll children, pregnant or breastfeeding individuals, or prisoners. Individuals with impaired decision-making capacity may be enrolled only when a legally authorized representative is available to provide consent in accordance with institutional and regulatory requirements.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Terapia di supporto
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Dexamethasone Arm
Standard dexamethasone (steroid) treatment
|
Potent FDA-approved corticosteroid
|
|
Nessun intervento: No-dexamethasone Arm
No routine dexamethasone treatment
|
|
|
Sperimentale: Azeliragon Arm
Azeliragon administered for the treatment of brain cancer and to evaluate its capability to control brain swelling around the time of surgery.
|
orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE)
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
change in peritumoral edema between the preoperative and postoperative period
Lasso di tempo: before the start of adjuvant chemo radiation (up to 6 weeks)
|
The primary outcome is the change in peritumoral edema between the preoperative and postoperative period.
Specifically, it is the ratio of postoperative to preoperative peritumoral edema volume, adjusted for extent of enhancing tumor removed.
This outcome is derived from MRI-based volumetric assessment and reflects the effectiveness of each perioperative strategy in controlling cerebral edema while accounting for surgical factors
|
before the start of adjuvant chemo radiation (up to 6 weeks)
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Akshitkumar M Mistry, MD, UofL Health - Brown Cancer Center
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ROID-RAGE-HGG
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Periodo di condivisione IPD
Criteri di accesso alla condivisione IPD
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- ICF
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Dexamethasone
-
Loyola UniversityMerck Sharp & Dohme LLCCompletato